WestView Capital Partners has taken a minority stake in Helio Health Group, a life sciences AI company based in Morristown, New Jersey. The deal, announced Tuesday, provides capital for the company's next growth phase. Founded in 2015, Helio specializes in artificial intelligence applications for pharmaceutical and biotech clients.

The investment targets expansion across three core areas: life sciences compliance, government pricing, and commercialization. These sectors represent significant pain points for drug companies navigating complex regulatory environments and reimbursement challenges. Helio's leadership team—Marci Juneau, John Poulin, and Manny Tzavlakis—will retain control while significantly growing their workforce and technical capabilities.

Minority investments like this typically signal institutional confidence without major ownership changes. WestView's backing suggests strong momentum in AI-driven life sciences solutions, particularly as pharmaceutical companies increasingly seek automation for regulatory compliance and pricing strategies. The capital infusion positions Helio to compete more aggressively for enterprise contracts.

This investment reflects broader private equity interest in healthcare technology platforms serving the $1.2 trillion global pharmaceutical market. Companies that can streamline compliance and pricing processes command premium valuations as drug developers face mounting pressure to reduce operational costs.